(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight in a late-stage ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

Copycat weight loss drugs on the rise Weight loss hacks promising quick fixes for slimming have a long history. But they have risen to a whole new level since Ozempic and Wegovy became popular.

New trial results show the weight-loss medication Wegovy can also cut heart attack and stroke risks, according to the drug's maker. The maker of Wegovy is claiming the weight loss drug can also ...

Weight-loss drugs Mounjaro and Wegovy gain popularity among Indian diabetes patients. New research highlights rare but ...

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...